Management of Von Willebrand Disease Type 2
For patients with von Willebrand disease type 2, use plasma-derived or recombinant von Willebrand factor (vWF) concentrates as the primary treatment, with critical attention to subtype-specific considerations—particularly avoiding desmopressin (DDAVP) in type 2B due to risk of platelet clumping and thrombocytopenia. 1
Subtype-Specific Management Approach
Type 2A, 2M, and 2N VWD
Primary therapy: Plasma-derived or recombinant vWF concentrates provide adequate levels of functional vWF and factor VIII (FVIII). These concentrates are the mainstay of treatment for all type 2 variants 1.
DDAVP consideration: While DDAVP is generally not first-line for type 2 VWD, it may be useful in select type 2M cases with nearly normal multimeric patterns 2. However, a trial test must always be performed before relying on DDAVP (except in type 2B where it is contraindicated), as no laboratory test accurately predicts response 2.
For type 2N specifically (defective vWF binding to FVIII):
- When FVIII and vWF levels are <50 IU/dL, treatment options include DDAVP, antifibrinolytics, and factor replacement 1
- FVIII levels will be reduced to 0.05-0.40 IU/mL 3
Type 2B VWD - Critical Contraindication
DDAVP is absolutely contraindicated in type 2B VWD because it causes platelet clumping and consumption, worsening the thrombocytopenia that already characterizes this subtype 1, 4.
Specific management for type 2B:
- vWF concentrates remain the primary therapy
- Platelet transfusions may be needed in addition to vWF concentrates due to the enhanced platelet binding and consumption 1
- Thrombocytopenia can be exacerbated by physiologic stressors such as pregnancy 4
Perioperative and Procedural Management
Surgical Hemostasis Targets
For major surgery:
- Maintain vWF and FVIII levels >50 IU/dL 1
- Dosing: 40-60 IU/kg of vWF-containing factor concentrate initially, then once daily 1
- Duration: Continue for 5-7 days postoperatively 1
Adjunctive Therapy
Antifibrinolytics (e.g., tranexamic acid) are valuable adjuncts across all type 2 subtypes:
- Particularly useful for procedures with high fibrinolytic activity 1
- Essential in postpartum management: continue for 2 weeks after delivery or longer 1
- Can be used alongside factor replacement 1
Pregnancy and Delivery Management
For women with type 2 VWD during pregnancy:
- Maintain vWF and FVIII levels >50 IU/dL for 5-7 days postpartum 1
- Administer 40-60 IU/kg vWF concentrate at delivery, then daily 1
- Add antifibrinolytics for 2 weeks postpartum 1
Critical Pitfalls to Avoid
Never use DDAVP in type 2B without prior testing - this can precipitate dangerous thrombocytopenia 1, 4
Don't assume DDAVP will work in type 2 variants - response rates are much lower than in type 1 VWD, and a trial test is mandatory before relying on it 2
Don't forget platelet support in type 2B - vWF concentrates alone may be insufficient due to platelet consumption 1
Recognize gastrointestinal bleeding risk - particularly in type 2A, angiodysplasia-related GI bleeding is common and requires proactive endoscopic management 5, 6
Hematology Consultation
All factor concentrate prescriptions should be directed by a hematologist 1. The heterogeneity within type 2 VWD subtypes and variable bleeding phenotypes necessitate individualized dosing strategies that require specialized expertise 1, 2.
The severity of bleeding in type 2 VWD, particularly type 2A, tends to be greater than other variants, with manifestations including mucocutaneous bleeding, heavy menstrual bleeding, epistaxis, post-surgical bleeding, and GI hemorrhage 6. This underscores the importance of adequate prophylactic treatment for any invasive procedure.